Close Menu

NEW YORK – Myriad Genetics said it has submitted a supplementary premarket approval application to the US Food and Drug Administration for myChoice CDx as a companion diagnostic for olaparib (AstraZeneca/Merck's Lynparza) in combination with bevacizumab (Genentech's Avastin).

In January, the FDA accepted AstraZeneca and Merck's supplementary new drug application for the olaparib/bevacizumab combination and granted it priority review for the maintenance treatment of advanced ovarian cancer patients who are responding to first-line platinum chemotherapy with bevacizumab.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.